INTRODUCTION {#sec1}
============

Until recent years, vancomycin (VAN) has been the cornerstone antibiotic for the treatment of severe methicillin-resistant *Staphylococcus* spp. infections. However, the progressive loss of susceptibility of *Staphylococcus aureus* to VAN has led to the use in daily practice of doses higher than those approved by the Food and Drug Administration (1g/12h) to maintain its effectiveness \[[@cit0001]-[@cit0007]\]. Particularly, high-dose treatments targeting a serum trough concentration of 15-20 mg/L has been recommended in several guidelines \[[@cit0008]-[@cit0014]\]. This increasing dosage of VAN has been significantly associated with the development of renal failure in several studies \[[@cit0007],[@cit0015]-[@cit0019]\]. The incidence of nephrotoxicity related with VAN treatment varies greatly due to the different baseline characteristics of the populations evaluated and the different dosing regimens. Available data suggests its association with concomitant administration of nephrotoxic agents, high serum trough levels, and prolonged duration of therapy \[[@cit0015],[@cit0020],[@cit0021]\]. This is important since small increases in serum creatinine of hospitalized patients are associated with increased mortality, hospital stay and health costs \[[@cit0022]-[@cit0024]\].

Alternative compounds such as daptomycin (DAP) and linezolid, specific agents against Gram-positive infections, have demonstrated to be less nephrotoxic than VAN (as comparator drug at 1g/12h) \[[@cit0025],[@cit0026]\]. However, no comparative study has specifically evaluated nephrotoxicity as primary end-point between DAP and VAN.

The aim of the present study was to evaluate nephrotoxicity development in patients treated with VAN and DAP for severe Gram-positive infections, and factors associated with it, in daily practice.

MATERIALS AND METHODS {#sec2}
=====================

**Study design and population.** A practice-based, observational, retrospective study was conducted to evaluate nephrotoxicity in patients admitted to eight Spanish hospitals with proven Gram-positive cocci infections that had been treated with DAP or VAN according to clinical practice. The study protocol was approved by the Ethical Review Board of Hospital Central de la Defensa Gomez Ulla, Madrid, Spain.

Clinical records of antibiotic-treated patients discharged from Internal Medicine Departments of participating hospitals, at least six months prior to study approval, were reviewed and studied if they were patients ≥18 years of age that had received parenteral DAP or VAN treatment for \>48 h, and had a baseline glomerular filtration rate (GFR)\>30 mL/min and/or a serum creatinine level \<2 mg/dL. Transplant recipients, patients presenting neutropenia (\<1000 neutrophils/mm^3^), AIDS (≤ 200 CD4/mm^3^), and concomitant disease or infection that in opinion the investigator might confound the results of the study were not considered. Medical records were reviewed for demographic, clinical (concomitant antibiotic treatment, length of treatment, outcome...), microbiological and analytical data.

**Study definitions.** Nephrotoxicity was defined as a decrease in baseline GRF to \<50 mL/min or a decrease of \>10 mL/min from a baseline GRF \<50 mL/min. Clinical response was considered as resolution or improvement of baseline signs/symptoms. Clinical failure was defined as death, persistence or worsening of baseline signs/symptoms, emergence of new signs/symptoms, or requirement of additional antibiotics different from those empirically prescribed. Microbiological response was considered as eradication (negative cultures after treatment) or absence of post-treatment cultures due to favourable clinical response. Patients were assessed at the end of parenteral treatment and until hospital discharge or death. Standard definitions for sepsis, severe sepsis or septic shock were employed \[[@cit0027]\].

**Statistical analysis.** Differences between treatments were assessed by t test or U-Mann-Whitney non-parametric tests (continuous variables) or by Chi square/Fish exact tests (discrete variables). Significance level was established at p ≤ 0.05. Several stepwise logistic regression multivariate analyses were conducted in order to determine: 1) factors associated with treatment selection, 2) factors associated with development of nephrotoxicity, 3) factors associated with development of nephrotoxicity among patients treated with VAN, and 4) factors associated with development of nephrotoxicity among patients treated with DAP. All variables showing differences in bivariate analyses (p \<0.1) were considered for inclusion in the models. In addition, based on the well-known nephrotoxicity of aminoglycosides, concomitant administration of these drugs was introduced in the model as independent variable. All statistical calculations were computed using SAS system version 9.2^®^ for Windows^®^

RESULTS {#sec3}
=======

A total of 133 patients were included, 62 patients treated with DAP and 71 patients with VAN. The median (range) total daily dose for DAP was 390 mg (500 mg-700 mg), and for VAN, doses were 1-2g/12h, with 76.1% patients having received 2g/12h. Treatment duration \[median (interquartile range)\] was significantly higher for DAP \[15 (8-28.5) days\] than for VAN \[10 (6-15) days\] (p=0.002). Overall, nephrotoxicity occurred in 21 out of 133 (15.8%) patients: 4 out of 62 (6.3%) patients treated with DAP and 17 out of 71 (23.3%) with VAN (p=0.006). Median (interquartile range) time to nephrotoxicity was 9.5 (2.8-29.8) days with DAP and 7.0 (4.0-18.5) days with VAN (p=0.893).

[Table 1](#t0001){ref-type="table"} shows microorganisms isolated and concomitant antibiotics. Drugs other than antibiotics with potential nephrotoxicity (furosemide, salicylic acid, non-steroidal anti-inflammatory drugs...) were administered to 15 out of 133 (11.3%) patients, without differences between antibiotic groups and between patients developing or not nephrotoxicity. Methicillin-resistant *S. aureus* (MRSA) accounted for 29.3% of all isolates. The percentage of the different species isolated did not show differences between groups. With respect to concomitant antibiotics during DAP or VAN treatment, β-lactams administration was more frequent among patients not developing nephrotoxicity, with cephalosporins more frequently used among patients receiving VAN (vs. DAP).

###### 

Isolated microorganisms, concomitant antibiotics and outcome

                                           Total (n=133)   Treatment with   Nephrotoxicity                                    
  ---------------------------------------- --------------- ---------------- ---------------- ------- ----------- ------------ -------
  CNS[^a^](#tf1-1){ref-type="table-fn"}    43 (32.3)       18 (29.0)        25 (35.2)        0.447   9 (42.9)    34 (30.4)    0.261
  MRSA[^b^](#tf1-2){ref-type="table-fn"}   39 (29.3)       22 (35.5)        17 (23.9)        0.145   3 (14.3)    36 (32.1)    0.099
  MSSA[^c^](#tf1-3){ref-type="table-fn"}   21 (15.8)       11 (17.7)        10 (14.1)        0.564   4 (19.0)    17 (15.2)    0.744
  *Enterococcus* spp.                      24 (18.0)       11 (17.7)        14 (19.7)        0.591   5 (23.8)    19 (17.0)    0.536
  Other Gram-positive bacteria             9 (6.8)         2 (3.2)          7 (9.9)          0.178   1 (4.8)     8 (7.1)      1.000
  Gram-negative bacteria                   5 (3.8)         2 (3.2)          3 (4.2)          1.000   1 (4.8)     4 (3.6)      0.583
  Concomitant antibiotics                  70 (53.0)       31 (58.8)        39 (54.9)        0.367   8 (38.1)    62 (55.4)    0.146
  Penicillins                              9 (6.8)         3 (4.8)          6 (8.5)          0.502   0 (0.0)     9 (8.0)      0.353
  Cephalosporins                           15 (11.3)       3 (4.8)          12 (16.9)        0.028   2 (9.5)     13 (11.6)    1.000
  Aztreonam                                2 (1.5)         2 (3.2)          0 (0.0)          0.215   0 (0.0)     2 (1.8)      1.000
  Carbapenem                               22 (16.5)       11 (17.7)        11 (15.5)        0.727   1 (4.8)     21 (18.8)    0.198
  Total β-lactams                          48 (36.1)       19 (30.6)        29 (40.8)        0.221   3 (14.3)    45 (40.2)    0.043
  Aminoglycosides                          13 (9.8)        5 (8.1)          8 (11.3)         0.383   4 (19.0)    9 (8.0)      0.125
  Quinolones                               13 (9.8)        5 (8.1)          8 (11.3)         0.383   1 (4.8)     12 (10.7)    0.691
  Rifampicin                               9 (6.8)         6 (9.7)          3 (4.2)          0.301   2 (9.5)     7 (6.3)      0.633
  Others                                   8 (6.0)         4 (6.5)          3 (4.2)          0.705   1 (4.8)     6 (5.4)      1.000
  Clinical cure                            117 (88.0)      55 (88.7)        62 (87.3)        0.806   15 (71.4)   102 (91.1)   0.011
  Eradication + presumed eradication       109 (82.2)      52 (83.9)        57 (80.3)        0.591   15 (71.4)   94 (83.9)    0.171

CNS: Coagulase-negative staphylococci

MRSA: Methicillin-resistant Staphylococcus aureus

MSSA: Methicillin-susceptible Staphylococcus aureus

[Tables 2](#t0002){ref-type="table"} and [3](#t0003){ref-type="table"} show characteristics of patients, comorbidities, and type and severity of infections distributing patients by antibiotic treatment and development of nephrotoxicity or not, respectively. More than 65% patients were ≥65 years old, without differences between antibiotic groups but being significantly higher the percentage of patients from this age group among those developing nephrotoxicity. Up to 31.6% patients had a Charlson index ≥3; median (interquartile range) index value for the study population was 2 (0-3), without differences between antibiotic groups or patients developing nephrotoxicity or not. Patients with sepsis/severe sepsis/septic shock represented 88.7% of the study population (118 out of 133 patients), without differences between groups.

###### 

Basal data potentially influencing antibiotic selection: patient's characteristics, comorbidities (present in \>9% patients), type of infection and severity. Data expressed as n (%) or mean ± SD

                                                                     Total (n=133)   Daptomycin (n=62)   Vancomycin (n=71)   p
  ------------------------------------------------------------------ --------------- ------------------- ------------------- -------
  Males                                                              85 (63.9)       44 (71.0)           41 (57.7)           0.113
  Age                                                                68.5 ± 15.2     67.9 ± 14.9         69.1 ± 15.4         0.656
  ≥65 years                                                          87 (65.4)       40 (64.5)           47 (66.2)           0.839
                                                                                                                             
  Congestive heart failure                                           36 (27.1)       16 (25.8)           20 (28.2)           0.760
  Diabetes mellitus (DM)                                             27 (20.3)       12 (19.4)           15 (21.1)           0.800
  COPD[^a^](#tf2-1){ref-type="table-fn"}                             23 (17.3)       8 (12.9)            15 (21.1)           0.211
  Acute myocardial infarction                                        20 (15.0)       5 (8.1)             15 (21.1)           0.036
  Malignancies                                                       23 (17.3)       9 (14.5)            14 (19.7)           0.429
  Dementia                                                           17 (12.8)       5 (8.1)             12 (16.9)           0.128
  Stroke                                                             16 (12.0)       3 (4.8)             13 (18.3)           0.017
  DM with organ lesion                                               13 (9.8)        9 (14.5)            4 (5.6)             0.085
  Hypertension                                                       12 (9.0)        9 (14.5)            3 (4.2)             0.039
  Basal GFR[^b^](#tf2-2){ref-type="table-fn"} (mL/min/1.73 m^2^)     63.5 ± 31.5     59.5 ± 31.2         67.2 ± 31.5         0.183
  Basal GFR[^b^](#tf2-2){ref-type="table-fn"} ≤50 mL/min/1.73 m^2^   49 (36.8)       26 (41.9)           23 (32.4)           0.255
  Basal creatinine (mg/dL)                                           1.0 ± 0.4       1.1 ± 0.4           1.0 ± 0.4           0.036
  Basal creatinine ≥0.9 mg/dL                                        71 (53.4)       40 (64.5)           31 (43.7)           0.017
  Basal creatinine \>1.2 mg/dL                                       40 (30.1)       23 (37.1)           17 (23.9)           0.099
  Basal creatinine clearance (mL/min)                                78.9 ± 37.4     73.8 ± 33.1         83.1 ± 40.4         0.242
  Basal creatinine clearance \<80 mL/min                             84 (63.2)       43 (69.4)           41 (57.7)           0.166
  Basal CPK[^c^](#tf2-3){ref-type="table-fn"} (U/L)                  155.0 ± 363.6   134.6 ± 196.2       171.9 ± 460.2       0.666
                                                                                                                             
  Osteoarticular infection                                           31 (23.3)       19 (30.6)           12 (16.9)           0.061
  Skin & Soft tissue infection                                       29 (21.8)       16 (25.8)           13 (18.3)           0.296
  Catheter-related bacteremia                                        26 (19.5)       11 (17.7)           15 (21.1)           0.623
  Endocarditis                                                       17 (12.8)       12 (19.4)           5 (7.0)             0.034
  Primary bacteremia                                                 15 (11.3)       2 (3.2)             13 (18.3)           0.006
  Intraabdominal infection                                           6 (4.5)         1 (1.6)             5 (7.0)             0.215
  Respiratory infection                                              4 (3.0)         0 (0.0)             4 (5.6)             0.124
  Urinary tract infection                                            7 (5.3)         2 (3.2)             5 (7.0)             0.448
  Others                                                             11 (8.3)        5 (8.1)             6 (8.5)             0.936
  Sepsis                                                             97 (72.9)       43 (69.4)           54 (76.1)           0.778
  Severe sepsis                                                      16 (12.0)       9 (14.5)            7 (9.9)             0.410
  Shock                                                              5 (3.8)         3 (4.8)             2 (2.8)             0.663

COPD: Chronic obstructive pulmonary disease

GFR: Glomerular filtration rate

CPK: Creatine phosphokinase

###### 

Basal data potentially influencing development of nephrotoxicity: patient's characteristics, comorbidities (present in \>9% patients), type of infection and severity. Data expressed as n (%) or mean ± SD

                                                                     Nephrotoxicity                                  
  ------------------------------------------------------------------ ---------------- --------------- -------------- ---------
  Males                                                              85 (63.9)        10 (47.6)       75 (67.0)      0.090
  Age                                                                68.5 ± 15.2      75.9 ± 8.3      67.2 ± 15.8    0.001
  ≥65 years                                                          87 (65.4)        19 (90.5)       68 (60.7)      0.009
                                                                                                                     
  Congestive heart failure                                           36 (27.1)        10 (47.6)       26 (23.2)      0.021
  Diabetes mellitus (DM)                                             27 (20.3)        5 (23.8)        22 (19.6)      0.768
  COPD[^a^](#tf3-1){ref-type="table-fn"}                             23 (17.3)        5 (23.8)        18 (16.1)      0.363
  Acute myocardial infarction                                        20 (15.0)        4 (19.0)        16 (14.3)      0.522
  Malignancies                                                       23 (17.3)        1 (4.8)         22 (19.6)      0.039
  Dementia                                                           17 (12.8)        3 (14.3)        14 (12.5)      0.733
  Stroke                                                             16 (12.0)        5 (23.8)        11 (9.8)       0.134
  DM with organ lesion                                               13 (9.8)         4 (19.0)        9 (8.0)        0.126
  Hypertension                                                       12 (9.0)         1 (4.8)         11 (9.8)       0.690
  Basal GFR[^b^](#tf3-2){ref-type="table-fn"} (mL/min/1.73 m^2^)     63.5 ± 31.5      63.9 ± 32.4     61.2 ± 25.8    0.738
  Basal GFR[^b^](#tf3-2){ref-type="table-fn"} ≤50 mL/min/1.73 m^2^   49 (36.8)        8 (38.1)        41 (36.6)      0.896
  Basal creatinine (mg/dL)                                           1.0 ± 0.4        1.0 ± 0.4       1.2 ± 0.4      0.085
  Basal creatinine ≥0.9 mg/dL                                        71 (53.4)        16 (76.2)       55 (49.1)      0.022
  Basal creatinine \>1.2 mg/dL                                       40 (30.1)        13 (61.9)       27 (24.1)      \<0.001
  Basal creatinine clearance (mL/min)                                78.9 ± 37.4      83.0 ± 38.9     52.7 ± 19.9    \<0.001
  Basal creatinine clearance \<80 mL/min                             84 (63.2)        19 (90.5)       65 (58.0)      0.005
  Basal CPK[^c^](#tf3-3){ref-type="table-fn"} (U/L)                  155.0 ± 363.6    165.0 ± 395.9   104.1 ± 82.5   0.599
                                                                                                                     
  Osteoarticular infection                                           31 (23.3)        5 (23.8)        26 (23.2)      1.000
  Skin & Soft tissue infection                                       29 (21.8)        4 (19.0)        25 (22.3)      1.000
  Catheter-related bacteremia                                        26 (19.5)        2 (9.5)         24 (21.4)      0.367
  Endocarditis                                                       17 (12.8)        5 (23.8)        12 (10.7)      0.146
  Primary bacteremia                                                 15 (11.3)        1 (4.8)         14 (12.5)      0.464
  Intraabdominal infection                                           6 (4.5)          1 (4.8)         5 (4.5)        1.000
  Respiratory infection                                              4 (3.0)          1 (4.8)         3 (2.7)        0.501
  Urinary tract infection                                            7 (5.3)          2 (9.5)         5 (4.5)        0.305
  Others                                                             11 (8.3)         1 (4.8)         10 (8.9)       1.000
  Sepsis                                                             97 (72.9)        15 (71.4)       82 (73.2)      0.865
  Severe sepsis                                                      16 (12.0)        4 (19.0)        12 (10.7)      0.281
  Shock                                                              5 (3.8)          1 (4.8)         10 (8.9)       1.000

COPD: Chronic obstructive pulmonary disease

GFR: Glomerular filtration rate

CPK: Creatine phosphokinase

In bivariate analysis ([table 2](#t0002){ref-type="table"}), acute myocardial infarction and stroke (as comorbidities) and primary bacteremia (type of infection) were significantly more frequent among patients treated with VAN than among those with DAP, whereas hypertension, basal creatinine and endocarditis were more frequent among patients treated with DAP. In the multivariate analysis for treatment selection (R^2^=0.209; p\<0.001), factors associated with DAP treatment were diabetes mellitus (DM) with organ lesion (OR=7.81, 95%CI: 1.39-4.35) and basal creatinine ≥0.9 mg/dL (OR=2.53, 95%CI: 1.15-4.35) while factors associated with VAN treatment were stroke (OR=7.22, 95%CI: 1.50-34.67), acute myocardial infarction (OR=6.59, 95%CI: 1.51-28.69) and primary bacteremia (OR=5.18, 95%CI: 1.03-25.99).

Basal creatinine values were significantly higher and creatinine clearance lower among patients developing nephrotoxicity during treatment ([table 3](#t0003){ref-type="table"}), with higher percentage of patients with congestive heart failure. On the contrary, the percentage of patients with malignancies was higher among patients not developing nephrotoxicity. In the multivariate analysis (R^2^=0.142; p=0.001), factors associated with nephrotoxicity were basal creatinine clearance \<80 mL/min (OR=9.22, 95%CI: 1.98-30.93) and treatment with VAN (OR=6.07, 95%CI: 1.86-19.93).

[Table 4](#t0004){ref-type="table"} shows basal data potentially influencing development of nephrotoxicity for patients treated with VAN. In the bivariate analysis, patients developing nephrotoxicity were significantly older and presented more frequently congestive heart failure, higher values of basal creatinine and lower values of basal creatinine clearance. In the multivariate analysis (R^2^=0.232; p=0.018), factors associated with nephrotoxicity were congestive heart failure (OR=4.35, 95%CI: 1.23-15.37), endocarditis (OR=7.63, 95%CI: 1.02-57.31) and basal creatinine clearance \<80 mL/min (OR=7.73, 95%CI: 1.20-49.71).

###### 

Basal data potentially influencing development of nephrotoxicity for patients treated with vancomycin: patient's characteristics, comorbidities (present in \>9% patients), type of infection and severity. Data expressed as n (%) or mean ± SD

                                                                     Nephrotoxicity                   
  ------------------------------------------------------------------ ---------------- --------------- -------
  Males                                                              8 (47.1)         33 (61.1)       0.306
  Age                                                                75.8 ± 8.0       67.0 ± 16.6     0.004
  ≥65 years                                                          15 (88.2)        32 (59.3)       0.039
                                                                                                      
  Congestive heart failure                                           10 (58.8)        10 (18.5)       0.004
  Diabetes mellitus (DM)                                             3 (17.6)         12 (22.2)       1.000
  COPD[^a^](#tf4-1){ref-type="table-fn"}                             4 (23.5)         11 (20.4)       0.745
  Acute myocardial infarction                                        4 (23.5)         11 (20.4)       0.745
  Malignancies                                                       1 (5.9)          13 (24.1)       0.162
  Dementia                                                           3 (17.6)         9 (16.7)        1.000
  Stroke                                                             5 (29.4)         8 (14.8)        0.278
  DM with organ lesion                                               2 (11.8)         2 (3.7)         0.241
  Hypertension                                                       0 (0.0)          3 (5.6)         1.000
  Basal GFR[^b^](#tf4-2){ref-type="table-fn"} (mL/min/1.73 m^2^)     66.3 ± 25.5      67.4 ± 33.2     0.910
  Basal GFR[^b^](#tf4-2){ref-type="table-fn"} ≤50 mL/min/1.73 m^2^   5 (29.4)         18 (33.3)       0.763
  Basal creatinine (mg/dL)                                           1.1 ± 0.4        0.9 ± 0.3       0.100
  Basal creatinine ≥0.9 mg/dL                                        12 (70.6)        19 (35.2)       0.010
  Basal creatinine \>1.2 mg/dL                                       7 (41.2)         7 (13.0)        0.030
  Basal creatinine clearance (mL/min)                                54.1 ± 22.4      89.7 ± 40.8     0.003
  Basal creatinine clearance \<80 mL/min                             15 (88.2)        26 (48.1)       0.035
  Basal CPK[^c^](#tf4-3){ref-type="table-fn"} (U/L)                  104.1 ± 82.5     200.9 ± 547.9   0.549
                                                                                                      
  Osteoarticular infection                                           4 (23.5)         8 (14.8)        0.463
  Skin & Soft tissue infection                                       3 (17.6)         10 (18.5)       1.000
  Catheter-related bacteremia                                        2 (11.8)         13 (24.1)       0.496
  Endocarditis                                                       3 (17.6)         2 (3.7)         0.085
  Primary bacteremia                                                 1 (5.9)          12 (22.2)       0.167
  Intraabdominal infection                                           1 (5.9)          4 (7.4)         1.000
  Respiratory infection                                              1 (5.9)          3 (5.6)         1.000
  Urinary tract infection                                            2 (11.8)         3 (5.6)         0.587
  Others                                                             1 (5.9)          5 (9.3)         1.000
  Sepsis                                                             12 (70.6)        42 (77.8)       0.532
  Severe sepsis                                                      3 (17.6)         4 (7.4)         0.346
  Shock                                                              1 (5.9)          1 (1.9)         0.424

COPD: Chronic obstructive pulmonary disease

GFR: Glomerular filtration rate

CPK: Creatine phosphokinase

[Table 5](#t0005){ref-type="table"} shows basal data potentially influencing development of nephrotoxicity for patients treated with DAP. All patients developing nephrotoxicity presented a basal GFR ≤50 mL/min/1.73 m^2^. In the multivariate analysis (R^2^=0.080; p=0.029) only DM with organ lesion (OR=[@cit0016].00, 95%CI: 1.25-204.11) was associated with nephrotoxicity.

###### 

Basal data potentially influencing development of nephrotoxicity for patients treated with daptomycin: patient's characteristics, comorbidities (present in \>9% patients), type of infection and severity. Data expressed as n (%) or mean ± SD

                                                                     Nephrotoxicity                   
  ------------------------------------------------------------------ ---------------- --------------- -------
  Males                                                              2 (50.0)         42 (72.4)       0.573
  Age                                                                76.0 ± 10.8      67.3 ± 15.1     0.209
  ≥65 years                                                          4 (100)          36 (62.1)       0.287
                                                                                                      
  Congestive heart failure                                           0 (0.0)          16 (27.6)       0.565
  Diabetes mellitus (DM)                                             2 (50.0)         10 (17.2)       0.166
  COPD[^a^](#tf5-1){ref-type="table-fn"}                             1 (25.0)         7 (12.0)        0.433
  Acute myocardial infarction                                        0 (0.0)          5 (8.6)         1.000
  Malignancies                                                       0 (0.0)          9 (15.5)        1.000
  Dementia                                                           0 (0.0)          5 (8.6)         1.000
  Stroke                                                             0 (0.0)          3 (5.2)         1.000
  DM with organ lesion                                               2 (50.0)         7 (12.1)        0.097
  Hypertension                                                       1 (25.0)         8 (13.8)        0.475
  Basal GFR[^b^](#tf5-2){ref-type="table-fn"} (mL/min/1.73 m^2^)     37.0 ± 7.0       60.7 ± 31.6     0.085
  Basal GFR[^b^](#tf5-2){ref-type="table-fn"} ≤50 mL/min/1.73 m^2^   4 (100)          23 (39.7)       0.031
  Basal creatinine (mg/dL)                                           1.5 ± 0.4        1.1 ± 0.4       0.061
  Basal creatinine ≥0.9 mg/dL                                        4 (100)          36 (62.1)       0.287
  Basal creatinine \>1.2 mg/dL                                       3 (75.0)         20 (34.5)       0.139
  Basal creatinine clearance (mL/min)                                48.4 ± 11.7      75.8 ± 33.4     0.170
  Basal creatinine clearance \<80 mL/min                             4 (100)          39 (67.2)       0.302
  Basal CPK[^c^](#tf5-3){ref-type="table-fn"} (U/L)                  186.2 ± 240.2    134.6 ± 199.2   1.000
                                                                                                      
  Osteoarticular infection                                           1 (25.0)         18 (31.0)       1.000
  Skin & Soft tissue infection                                       1 (25.0)         15 (25.9)       1.000
  Catheter-related bacteremia                                        0 (0.0)          11 (19.0)       1.000
  Endocarditis                                                       2 (50.0)         10 (17.2)       0.166
  Primary bacteremia                                                 0 (0.0)          2 (3.4)         1.000
  Intraabdominal infection                                           0 (0.0)          1 (1.7)         1.000
  Respiratory infection                                              0 (0.0)          0 (0.0)         \-
  Urinary tract infection                                            0 (0.0)          2 (3.4)         1.000
  Others                                                             0 (0.0)          5 (8.6)         1.000
  Sepsis                                                             3 (75.0)         40 (69.0)       1.000
  Severe sepsis                                                      1 (25.0)         8 (13.8)        0.475
  Shock                                                              0 (0.0)          3 (5.2)         1.000

COPD: Chronic obstructive pulmonary disease

GFR: Glomerular filtration rate

CPK: Creatine phosphokinase

No differences in outcome were found between antibiotics (88.7% for DAP vs. 87.3% for VAN), but the percentage of clinical cure among patients developing nephrotoxicity was significant lower (71.4% vs. 91.1% for patients without nephrotoxicity, p=0.011). Eradication or presumed eradication was obtained in 82.2% patients without differences between groups.

DISCUSSION {#sec4}
==========

The present study, to our knowledge the first comparative study assessing VAN- and DAP- induced nephrotoxicity in the treatment of Gram-positive infections in the uncontrolled setting of daily medical practice, showed significantly higher nephrotoxicity among patients treated with VAN than with DAP, not attributable to previous conditions or concomitant treatment with other potential nephrotoxic drugs.

In the literature, high daily doses of VAN providing serum trough levels of 15-20 mg/L, which are recommended when the MIC for MRSA is \>1 mg/L, have been independently associated with an increased risk of nephrotoxicity \[[@cit0007],[@cit0015]-[@cit0019]\]. A recent retrospective multicenter study with VAN trough levels of 17 mg/L concluded that rates of acute kidney injury were significantly lower in the DAP group in the treatment of bloodstream infections \[[@cit0028]\]. Two clinical trials, compared DAP with VAN at the dose of 1 g every 12 h \[[@cit0025],[@cit0029]\]. Arbeit et al. in a study analysing patients with complicated skin and skin soft tissue infections did not document significant statistical differences between both antibiotics (DAP 2.2% vs VAN 2.7%; p \>0.05) \[[@cit0029]\]. On the contrary, Fowler et al. in a randomized controlled trial that evaluated DAP versus standard therapy (VAN or antistaphylococcal penicillin ± gentamicin) in patients with *S. aureus* bacteremia and endocarditis reported higher rates of nephrotoxicity with VAN (18.1% vs 6.7% with DAP; p= 0.009) \[[@cit0025]\]. However, the incidence of renal impairment was similar among patients who received gentamicin and VAN (20.4%) and patients who received gentamicin and an antistaphylococcal penicillin (18.6%) \[[@cit0025]\]. Thus, as reported, the presence of other nephrotoxic factors such as aminoglycosides and a great variety of comorbidities confound the VAN-induced nephrotoxicity \[[@cit0020]\]. For these reasons, the present study was carried out to assess factors associated with treatment selection in daily practice and development of nephrotoxicity in a non-selected population with different comorbidities. Although the retrospective nature of the study represents a limitation, the lack of differences between groups in the administration of potential nephrotoxic drugs as aminoglycosides and in responsible microorganisms, as well as the presence of different comorbidities, strength the value of the present practice-based analysis.

The study population can be clearly considered elderly (65.4% were ≥65 years old) with comorbidities (31.6% patients had a Charlson index ≥3) and with moderate-severe infections (88.7% patients presenting sepsis/severe sepsis/septic shock). One important study finding was that osteoarticular infections accounted for 23.3% infections, with higher percentage among patients treated with DAP (30.6% vs. 16.9% for VAN; p=0.061), with no approved indication. However, two previous studies specifically assessed DAP treatment in this type of infections, one retrospective cohort study showing similar efficacy and safety than VAN \[[@cit0030]\], and one prospective study in combination with rifampicin \[[@cit0031]\].

Of importance, basal creatinine ≥0.9 mg/dL and DM with organ lesion were factors associated with DAP treatment, suggesting that this antibiotic was majority chosen for patients with suspicion of possible future nephrotoxicity. Regardless this fact, development of nephrotoxicity was associated with basal creatinine clearance \<80 mL/min and treatment with VAN. Therefore, the present study showed that nephrotoxicity with VAN was significantly higher than with DAP despite the poorer basal renal status in the DAP group and absence of differences in aminoglycosides use as concomitant antibiotic. The role of comorbidities could be assessed within the VAN group, nephrotoxicity being associated with congestive heart failure and endocarditis while within the DAP group it was associated with DM with organ lesion, although the small number of patients developing nephrotoxicity in this group weakens the data.

In conclusion, the present practice-based study showed that among hospitalized elderly population with Gram-positive severe infections, treatment selection was associated with comorbidities and basal values of creatinine, and nephrotoxicity was associated with VAN treatment and not to other concomitant antibiotics.
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